UnknownNot Applicable

Different Doses of vPDT in the Treatment of cCSC

China100 participantsStarted 2020-01-01

Plain-language summary

This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment group. The primary treatment success rate and adverse event rate of the two groups were compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for chronic CSC was summarized.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18-75 years old, regardless of gender; * Meet the diagnostic criteria of central serous chorioretinopathy; * The course of CSC (subject to the symptoms of this disease) is more than 3 months; * Patients with simultaneous diseases of both eyes were included in those with more subretinal fluid. Exclusion Criteria: * macular neuroretinal detachment caused by rhegmatogenous retinal detachment, uveitis, age-related macular degeneration, polypoid choroidal angiopathy and other fundus diseases; * a previous history of PDT treatment; * systemic hormone or local hormone nasal spray is being used, or hormone is stopped for less than 3 months.

What they're measuring

The complete absorption rate of subretinal fluid

Timeframe: 3 months after the primary PDT

Trial details

NCT IDNCT05390619

SponsorPeking University People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-31

Contact for this trial

Yuou Yao, Dr

13651177854 yaoyoyo19@139.com

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials